Pregnancy during adjuvant tamoxifen therapy: A case of temporary interruption and postpartum metastatic recurrence
DOI:
https://doi.org/10.59692/jogeca.v37i3.420Keywords:
breast cancer, endocrine therapy, metastasis, pregnancy, tamoxifenAbstract
Background: Limited data exist regarding recurrence risk in pregnant women with hormone receptor-positive breast cancer who temporarily discontinue endocrine therapy.
Case presentation: A 37-year-old gravida 4, para 3, presented for antenatal care at 13 weeks’ gestation while on adjuvant tamoxifen, which she had taken for two months before conception. Examination revealed a fundal height of 18 weeks and a healed mastectomy scar. Ultrasonography confirmed a dichorionic diamniotic twin pregnancy. Tamoxifen was discontinued, and pregnancy proceeded uneventfully until spontaneous preterm delivery at 34 weeks. Both neonates were clinically normal. Tamoxifen was resumed postpartum; however, 5 months after delivery, the patient developed metastatic recurrence and subsequently succumbed.
Conclusion: Pregnancy during breast cancer is not uncommon and poses complex clinical challenges. A multidisciplinary team is key to optimize maternal and neonatal outcomes.
Keywords: breast cancer, endocrine therapy, metastasis, pregnancy, tamoxifen
References
Kenya Medical Research Institute. Nairobi cancer registry: Cancer incidence report 2000-2002. Nairobi: Kenya Medical Research Institute; 2006 Oct. Available from: https://www.healthresearchweb.org/les/CancerIncidenceReportKEMRI.pdf.
Kadakia KC, Henry NL. Adjuvant endocrine therapy in premenopausal women with breast cancer. Clin Adv Hematol Oncol. 2015;13(10):663-672.
Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174-4183. doi:10.1200/JCO.2004.01.159
Anderson RA, Lambertini M, Hall PS, Wallace WH, Morrison DS, Kelsey TW. Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy. Eur J Cancer. 2022;173:113-122. doi:10.1016/j.ejca.2022.06.048
Partridge AH, Niman SM, Ruggeri M, et al. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. N Engl J Med. 2023;388(18):1645-1656. doi:10.1056/NEJMoa2212856
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer, Version 4.2025. NCCN.org. Updated April 30, 2025. Accessed October 7, 2025. https://www.nccn.org/guidelines/guidelines-detail?id=1419
Athman Omar AM, Abdel-Bary A, Elsaka RO. Tamoxifen exposure in pregnancy after synchronous breast and thyroid cancer. Ecancermedicalscience. 2020;14:1125. Published 2020 Oct 15. doi:10.3332/ecancer.2020.1125
Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16(11):1547-1551. doi:10.1634/theoncologist.2011-0121
Loibl S, Azim HA Jr, Bachelot T, et al. ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC). Ann Oncol. 2023;34(10):849-866. doi:10.1016/j.annonc.2023.08.001
Hartnett KP, Mertens AC, Kramer MR, et al. Pregnancy after cancer: Does timing of conception affect infant health?. Cancer. 2018;124(22):4401-4407. doi:10.1002/cncr.31732
Buonomo B, Brunello A, Noli S, et al. Tamoxifen Exposure during Pregnancy: A Systematic Review and Three More Cases. Breast Care (Basel). 2020;15(2):148-156. doi:10.1159/000501473
MacCallum J, Cummings J, Dixon JM, Miller WR. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer. 2000;82(10):1629-1635. doi:10.1054/bjoc.2000.1120
Moorthie S, Blencowe H, Darlison MW, et al. Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide. J Community Genet. 2018;9(4):387-396. doi:10.1007/s12687-018-0384-2
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2025 Dr. Morris Maganjo, Professor Rose Kosgei, Dr. Humphrey Obwaya, Dr. Allan Ikol, Dr. Maurine Mutua

This work is licensed under a Creative Commons Attribution 4.0 International License.
